Among women ≤50 years, both cancer cohorts consistently showed higher frequencies of BIM deletion polymorphism than healthy volunteers (consecutive cancer cohort, 23% vs.13%, P = 0.005; metastatic cancer cohort, 25% vs. 13%, P = 0.010). The gene discussed is BCL2L11; the disease is metastatic malignant neoplasm.